| ||||
|
Cafergot Nance imaging in migraine: clinical perspective [letter]. J Neurol Neurosurg Psychiatry 2003. : jnnp.bmjjournals cgi eletters 74 4 501#60. Published August 6, 2003. 3. Gupta VK. Cortical spreading depression is neuroprotective: the challenge of basic sciences. Headache 2005; 45: 177178. Gupta VK. Non-lateralizing brain PET changes in migraine: phenomenology versus pharmacology? [letter]. Brain 2004; 127: E12. doi: 10.1093 brain awh182. Published July 2004. 5. Gupta VK. Intractable cluster headache and therapeutic stimulation of the hypothalamus: pathophysiological and management insights from a rare experiment [letter]. Brain 2005; 128: E26. doi: 10.1093 brain awh392. Published April 2005. 6. Gupta VK. Stress, adaptation, and traumatic-event headaches: pathophysiologic and pharmacotherapeutic insights. BMC Neurology 2004; 4: 17. : biomedcentral 1471-2377 4 17 comments#106454. Published November 26, 2004. 7. Gupta VK. White matter hyperintensities: pearls and pitfalls in interpretation of MRI abnormalities. Stroke 2004; 35: 2756 Gupta VK. Lacunar stroke: on the threshold of a paradigm shift? [letter]. J Neurol Neurosurg Psychiatry 2005. : jnnp.bmjjournals cgi eletters 76 5 617#510. Published May 13, 2005. 9. Gupta VK. Transient global amnesia: consequent to brain hypoperfusion or hyperperfusion? [letter]. J Neurol Neurosurg Psychiatry 2005. : jnnp.bmjjournals cgi eletters 76 4 509#515. Published May 16, 2005. 10. Kobari M, Meyer JS, Ichijo M, Imai A, Oravez WT. Hyperperfusion of cerebral cortex, thalamus and basal ganglia during spontaneously occurring migraine headaches. Headache 1989; 29: 282289. Cafergot novartisIv ; after sub-rule 3 ; , the following shall be added, namely : -- " 4 ; fee of rupees fifty, which in no case shall be refundable, shall be paid for addition of additional items or item". 4. In the said rules in rule 33, after clause d ; following new clause shall be added, namely : -- " e ; The licensee shall obtain prior approval of the licensing authority for procurement of materials class of materials for the manufacture of drugs, indicating the name of the materials quantity, value, source and drugs to be manufactured with the raw materials so procured and further if the licensing authority so directs, the licensee shall submit invoices, documents or list of materials for subsequent verification as to whether materials have been procured in accordance with the prior approval given by the licensing authority." 5. In the said rules, in rule 34, i ; in sub-rule 1 ; , for the words "rupees twenty" and "rupees one hundred", the words "rupees two hundred" and "rupees three hundred" respectively shall be substituted; ii ; in sub-rule 2 ; , for the words "rupees ten", the words "rupees twenty five", shall be substituted; iii ; after sub-rule 2 ; , the following sub-rule shall be added, namely: -- " 3 ; If application for renewal is made within three after the expiry of the period of validity of a licence, the fee for fresh licence shall be Rs. 400 in addition to the inspection fee of Rs. 300 payable under sub-rule 1 ; "; and iv ; after sub-rule 3 ; , the following shall be added, namely : -- " 4 ; fee of rupees fifty, which in no case shall be refundable, shall be paid for addition of additional item or items". 6. In the said rules, in rule 37, the full stop at the end of clause K ; shall be substituted by a semi-colon and thereafter the following new clause shall be added, namely : " 1 ; The licensee shall obtain prior approval of the licensing authority for procurement of materials, class of materials for the manufacture of drugs, indicating the name of material, quantity, value, source and drugs to be manufactured with the raw materials so procured, and further if the licensing authority so directs, the licensee shall submit invoices, documents or lists of materials for subsequent verification as to whether materials have been procured in accordance with the prior approval given by the Licensing Authority". 7. In the said rules, in rule 41, for the words "rupees thirty", the words "rupees one hundred" shall be substituted. 8. In the said rules, in rule 53, sub-rule i ; shall be omitted. 9. In the said rules, for rule 62, the following shall be substituted, namely : "62. Additional provisions-- 1 ; The following shall be printed or written in indelible ink on the label of the container and on every other outer corner of the container : -- a ; the name and address of the manufacturer; b ; the true formula, except in case of ampules of 2 c.c. or less, where it will be sufficient to give true formula on the outer cover; and c ; a distinctive batch number, that is to say, the number by reference to which prescribed tests, and details of manufacture of the particular batch from which the substance in the container is taken are permanently recorded and available for inspection. Site the key to allergy relief - allergy symptoms and d person can be allergic to food, medications, dogs, cats, dust, mold, grass, etc the key to allergy relief with medication allergies the key to allergy relief is to not use the medications, for example, headaches. Sensitivity of some older individuals cannot be ruled out see CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations: Geriatric in the full prescribing information ; . ADVERSE REACTIONS The safety of OXYTROL was evaluated in a total of 417 patients who participated in two Phase 3 clinical efficacy and safety studies and an open-label extension. Additional safety information was collected in Phase 1 and Phase 2 trials. In the two pivotal studies, a total of 246 patients received OXYTROL during the 12-week treatment periods. A total of 411 patients entered the open-label extension and of those, 65 patients and 52 patients received OXYTROL for at least 24 weeks and at least 36 weeks, respectively. No deaths were reported during treatment. No serious adverse events related to treatment were reported. Adverse events reported in the pivotal trials are summarized in Tables 4 and 5 below. Table 4: Number % ; of adverse events occurring in 2% of OXYTROL-treated patients and greater in OXYTROL group than in placebo group Study 1 ; . OXYTROL 3.9 mg day ; L Adverse Event * Placebo N 132 ; N 125 ; N % N % Application site pruritus 8 6.1% 21 Dry mouth 11 8.3% 12 Application site erythema 3 2.3% 7 Application site vesicles 0 0.0% 4 3.2% Diarrhea 3 2.3% 4 Dysuria 0 0.0% 3 2.4% * includes adverse events judged by the investigator as possibly, probably or definitely treatment-related. Table 5: Number % ; of adverse events occurring in 2% of OXYTROL-treated patients and greater in OXYTROL group than in placebo group Study 2 ; . Adverse Event * Placebo OXYTROL 3.9 mg day ; N 117 ; N 121 ; N % N % Application site pruritus 5 4.3% 17 Application site erythema 2 1.7% 10 Dry mouth 2 1.7% 5 Constipation 0 0.0% 4 3.3% Application site rash 1 0.9% 4 Application site macules 0 0.0% 3 2.5% Abnormal vision 0 0.0% 3 2.5% * includes adverse events judged by the investigator as possibly, probably or definitely treatment-related. Other adverse events reported by 1% of OXYTROL-treated patients, and judged by the investigator to be possibly, probably or definitely related to treatment include: abdominal pain, nausea, flatulence, fatigue, somnolence, headache, flushing, rash, application site burning and back pain. Most treatment-related adverse events were described as mild or moderate in intensity. Severe application site reactions were reported by 6.4% of OXYTROL-treated patients in Study 1 and by 5.0% of OXYTROL-treated patients in Study 2. Treatment-related adverse events that resulted in discontinuation were reported by 11.2% of OXYTROL-treated patients in Study 1 and 10.7% of OXYTROL-treated patients in Study 2. Most of these were secondary to application site reaction. In the two pivotal studies, no patient discontinued OXYTROL treatment due to dry mouth. In the open-label extension, the most common treatment-related adverse events were: application site pruritus, application site erythema and dry mouth. DOSAGE AND ADMINISTRATION OXYTROL should be applied to dry, intact skin on the abdomen, hip, or buttock. A new application site should be selected with each new system to avoid re-application to the same site within 7 days. The dose of OXYTROL is one 3.9 mg day system applied twice weekly every 3 to 4 days ; . Storage Store at 25C 77F excursions permitted to 15 - 30C 59 - 86F ; . Protect from moisture and humidity. Do not store outside the sealed pouch. Apply immediately after removal from the protective pouch. Discard used OXYTROL in household trash in a manner that prevents accidental application or ingestion by children, pets, or others. Rx only. If possible, the trial should be reanalyzed indicating in detail which conclusions can or cannot be stated. References 1. Fastbom JBC, Schmidt I, Nordman Ch, Jallow A, Wahlstr m R, Lieberman-Ram H, Styrborn K 2003 ; Indikatorer fr utvrdering av kvaliteten i ldres lkemedelsterapi. Kunskapsversikt. Swedish National Board of Health and Welfare, Stockholm 2. Fastbom JBC, Olssob J, Olme B, Carlsten A, Schmidt I, Oke T 2004 ; Kvaliteten i ldres lkemedelsanvndning--KALLA projektet. Lgesbeskrivningar and calan. Note: For a description of references and other information, refer to the explanation of Committee tables and the accompanying notes at the end of this table. Footnotes: * Partially confirmed by bank information sources 10-14 ; * Fully confirmed by bank information sources 10-14 ; 1. Side agreement with Government of Iraq. 2. Ministry correspondence documents. 3. Company correspondence documents. 4. Other documents. 5. Ministry financial data. 6. Projected ASSF levied based on Government of Iraq policy documents. 7. Projected ASSF paid based on Government of Iraq policy documents. Represents contracts where inland transportation fee was required but no specific information was available 8. Projected Inland Transportation fees based on Government of Iraq policy documents. 9. Amount based on information provided by company and ministry documents. 10. Housing Bank for Trade and Finance Jordan ; , Central Bank of Iraq accounts Jan. 1, 2001 to Dec. 31, 2003 ; . 11. Jordan National Bank Jordan ; , Alia Company for Transport and General Trade accounts Mar. 1, 2000 to Dec. 31, 2003 ; . 12. Al-Rafidain Bank Jordan ; , Central Bank of Iraq accounts Jan. 1, 2000 to May 15, 2003 ; . 13. Fransabank SAL Lebanon ; , Central Bank of Iraq accounts Nov. 12, 2002 to Dec. 19, 2002 ; . 14. Jordan National Bank Jordan ; , Arrow Trans Shipping Company accounts May 1, 2001 to Dec. 31, 2001 ; . Page 251 of 381.
Cabergoline .29 Caduet 15 Cafwrgot 24 Calan 15 Calan SR .15 Calcijex 53 Calcitonin, Salmon, Synthetic 72 Calcitriol 43 Calcium Gluconate 53 Campath 53 Campral 39 Camptosar 11 Canasa 47 Cancidas . Cantil 45 Capastat Sulfate 53 Capex Shampoo 32 Caphosol 39 Capitrol 32 Capoten 12 Capozide 12 Captopril 12 Captopril Hydrochlorothiazide 12 Carac 35 Carac Cream 35 Carafate 47 Carafate Suspension .47 and capoten. Cafergot tabletsA trial of each of the preferred agents will be required before a non-preferred agent will be approved unless one of the exceptions on the PA form is present. Treatment naive patients must have a trial of a preferred agent before a nonpreferred agent in its corresponding class will be authorized. Patients stabilized on non-preferred agents will receive authorization to continue these drugs. Additions to that therapy will require a trial of preferred agent in its respective class unless one of the exceptions on the PA form is present. VIAL INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION TABLET, SUSTAINED ACTION TABLET, EFFERVESCENT VIAL VIAL VIAL INTRAVENOUS SOLUTION TABLET, EFFERVESCENT LIQUID ELIXIR LIQUID TABLET, SUSTAINED ACTION PACKET INTRAVENOUS SOLUTION INTRAVENOUS SOLUTION TABLET, SUST.RELEASE, PARTICLES CR YSTALS TABLET, SUST.RELEASE, PARTICLES CR YSTALS PACKET and levodopa. Cafergot medicineIntroduction Chemicals are associated with two types of hazard: hazards that are a direct result of the physical or reactive properties of a chemical; and hazards posed by the effect of a chemical on biological systems. Flammability and the stability of a chemical in air or towards water may be included in the first group, while the carcinogenic potential of a chemical or its effect on the reproductive system are health hazards due to the biological properties of a chemical. The different hazardous properties that Copy Editors should take into consideration when annotating experimental procedures are as follows: Physical and Reactive Chemical Hazards Flammability Explosive properties Stability in air or in contact with water pyrophoric and water-reactive compounds ; Incompatibility with commonly-available chemicals and reagents Potential for peroxidation Oxidizing reducing properties Storage properties Health Effects of Chemicals Known human carcinogens and probable human carcinogens according to the International Agency for Research on Cancer IARC ; classifications Known human teratogens Chemicals known to have an effect on human reproduction Chemicals that are irritants to the skin, eyes and respiratory system data from human exposure or animal tests ; Chemicals that are corrosive to the skin, eyes and respiratory system data from human exposure or animal tests ; Skin sensitizers Chemicals that are highly toxic as a result of some specific pharmacological mechanism e.g. the potent neurotoxin tetrodotoxin ; Apart from the necessity to be aware of hazardous properties before embarking on any manipulations with chemicals, hazard information is also required for risk assessments. It should be emphasised that hazard and risk are not interchangeable terms. Hazard is the set of inherent properties of a chemical substance that makes it capable of causing adverse effects in man or in the environment when a particular degree of exposure occurs. Risk is the prediction or actual frequency of occurrence of an adverse effect of a chemical substance from a given exposure to humans or the environment. In other words risk is a function of the physical, reactive or toxic properties of a chemical and the exposure to that substance. Risk assessment therefore requires knowledge of both the hazard of a chemical and the purpose for which it is being used. Risk assessments of hazardous substances used in the workplace are part of the regulatory framework for enacting national health and safety legislation. Some of the key regulations, which apply to laboratory safety in the UK, USA, and European Union, are described below and cilostazol. Nature's Plus Ultra Source of Life 180 Minitabletten Erweitertes VollwertMulti zur Erhhung der Energie. Eine vorbildlich zusammengestellte Vitalstoffformel fr hchste Ansprche. Ultra SOL enthlt alle Vitamine, Mineralstoffe und Spurenelemente, einen Vollwertkomplex, einen AminosureKomplex, Enzyme, einen Komplex zur Strkung der Gehirnleistung, einen AlgenKomplex, Bienenpollen, Ballaststoffe und Lutein zur Strkung der Augen. HypoAllergen, Vegetarisch, frei von Hefe, Weizen, Mais, Soja, Milch. Empfohlene tgliche Verzehrmenge: 26 Tabletten 22190 B Ultra C Rose Hips 2000 mg 60 Tabletten S R NP 24, 20, because zomig. CANTHARONE PLUS LIQUID TEGRETOL CR 200MG SA TABLET APO-ATENOL 50MG TABLET APO-ATENOL 100MG TABLET PMS-THIORIDAZINE 30MG ML M.O.S.-SR 30MG TABLET SA M.O.S. SR 60MG TABLET PMS-TRIFLUOPERAZINE 1MG ML AXID 150MG CAPSULE AXID 300MG CAPSULE APO-SULIN 150MG TABLET APO-SULIN 200MG TABLET NOVO-NAPROX SODIUM 275MG TB TOBRADEX OPHTHALMIC DROPS TOBRADEX OPHTHALMIC OINT NYADERM 100000U ML SUSP CODEINE PHOSPHATE 15MG TAB RATIO-CODEINE 25MG 5ML SYRP VOLTAREN SR 75MG TABLET SA APO-NADOL 80MG TABLET APO-NADOL 160MG TABLET APO-VERAP 80MG TABLET APO-VERAP 120MG TABLET APO-NADOL 40MG TABLET NOVO-CARBAMAZ 200MG TABLET FLEXERIL 10MG TABLET CAFERGOT SUPPOSITORY TRIKACIDE 500MG CAPSULE ISOTREX 0.05% GEL APO-NAPRO-NA 275MG TABLET APO-AMILZIDE TABLET NOVO-DIPIRADOL 25MG TABLET NOVO-DIPIRADOL 50MG TABLET NOVO-DIPIRADOL 75MG TABLET PMS-DEXAMETH SP 0.1% DROPS JAA AMP 125MG TABLET DILAUDID 1MG ML LIQUID DILAUDID 8MG TABLET BRICANYL 0.5MG TURBUHALER PMS-ISOSORBIDE 30MG TABLET PMS-ISOSORBIDE 10MG TABLET VANCOCIN 250MG CAPSULE PROCHLORPERAZINE 10MG SUPP TRIATEC-30 TABLET APO-SALVENT 100MCG INHALER APO-KETO 50MG CAPSULE APO-KETO-E 50MG TABLET EC TETRACYCLINE 1% EYE ONGUENT PMS-CHLORAL HYD 500MG 5ML PMS-NYSTATIN 100000U ML SUS PMS-OXTRIPHYLLINE 10MG ML and ciprofloxacin. NAMS POSITION STATEMENT stetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI; Adriane J. Fugh-Berman, MD, Associate Clinical Professor of Medicine, George Washington University School of Medicine, Washington, DC; Charles L. Loprinzi, MD, Professor of Oncology, Mayo Clinic, Rochester, MN; and Nancy King Reame, MSN, PhD, FAAN, Rhetaugh Dumas Professor of Nursing and Research Scientist, Reproductive Sciences Program, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI. Final review and approval was conducted by the 2002-2003 NAMS Board of Trustees: Margery L.S. Gass, MD President ; , Professor of Clinical Obstetrics and Gynecology, University of Cincinnati College of Medicine, and Director, University Hospital Menopause and Osteoporosis Center, Cincinnati, OH; James A. Simon, MD President-Elect ; , Clinical Professor of Obstetrics and Gynecology, George Washington University School of Medicine, Washington, DC; Bruce Kessel, MD Treasurer ; , Associate Professor, Department of Obstetrics and Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI; J. Christopher Gallagher, MD Secretary ; , Professor of Medicine, Creighton University, Department of Metabolism, St. Joseph's Hospital, Omaha, NE; Morrie M. Gelfand, CM, MD, Professor of Obstetrics and Gynecology, McGill University, and Honorary Chief, Department of Obstetrics and Gynecology, The Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada; George I. Gorodeski, MD, PhD, Professor of Reproductive Biology, Case Western Reserve University School of Medicine, Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Cleveland, OH; Gail A. Greendale, MD, Professor of Medicine and Obstetrics and Gynecology, David Geffen School of Medicine, Division of Geriatric Medicine, University of California, Los Angeles, CA; Victor W. Henderson, MD, MS, Professor of Geriatrics and Neurology, Center on Aging, University of Arkansas for Medical Sciences, Little Rock, AR; Betsy L. McClung, RN, MN, Associate Director, Oregon Osteoporosis Center, Portland, OR; Annette M. O'Connor, RN, PhD, Professor, University of Ottawa, Faculty of Health Sciences, School of Nursing, Faculty of Medicine, Department of Epidemiology and Community Medicine, Senior Scientist, Ottawa Health Research Institute, Ottawa HospitalCivic Campus, Ottawa, ON, Canada; Nancy King Reame, MSN, PhD, FAAN, Rhetaugh Dumas Professor of Nursing and Research Scientist, Reproductive Sciences Program, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI; Marcie K. Richardson, MD, Assistant Director of Obstetrics and Gynecology for Clinical Quality, The Copley Center, Harvard Vanguard Medical Associates, Boston, MA; Marilyn L. Rothert, PhD, RN, FAAN, Dean and Professor, College of Nursing, Michigan State University, East Lansing, MI; Isaac Schiff, MD Ex Officio ; , Joe Vincent Meigs Professor of Gynecology, Harvard Medical School, and Chief, Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital, Women's Care Division, Boston, MA; and Wulf H. Utian, MD, PhD Ex Officio ; , Arthur H. Bill Professor Emeritus of Reproductive Biology and Obstetrics and Gynecology, Case Western Reserve University School of Medicine, Consultant in Women's Health, Cleveland Clinic Foundation, and Executive Director, The North American Menopause Society, Cleveland, OH. The Society also acknowledges the valuable assistance of Andrew M. Kaunitz, MD, Professor and Assistant Chair, Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville, FL; Ian Graham, PhD, Senior Social Scientist and Associate Director, Clinical Epidemiology Program, Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada; Alastair H. MacLennan, MD, Department of Obstetrics and Gynaecology, University of Adelaide, Adelaide, Australia; as well as Philip K. Lammers, NAMS Medical Editor, and Pamela P. Boggs, MBA, NAMS Director of Education and Development. The development of this manuscript was supported by an unrestricted educational grant from Duramed Pharmaceuticals, Inc, a subsidiary of Barr Laboratories, Inc. Buy CafergotCafergot caffeine contentWhen taken in conjunction with caffeine and some herbal stimulates, ephedrine can over-stimulate the central nervous system, with potentially life threatening consequences and clindamycin and cafergot, for example, aspirin! Orally twice a day; and 30 mg of phenobarbital with one tablet of ergotamine Cafergot, Sandoz Pharmaceuticals ; , taken orally as needed for cluster headaches. The patient reported no known allergies. His social history included a 100 pack-year two packs a day X 50 years ; history of smoking cigarettes. He stated that he had stopped smoking cigarettes in the last year and currently smoked a pipe and seven to eight cigars each day. He also had a significant history of alcohol consumption; he said he had drunk several beers a day for. Any veterinarian found to be involved in the administration of any drug carrying the penalty category of "A" shall be referred to the State Licensing Board of Veterinary Medicine for consideration of further disciplinary action and or license revocation. This is in addition to any penalties issued by the stewards or the commission and clobetasol. 17. All of the following statements about right ventricular infarction are true except: A ; Right ventricular infarction usually occurs because of occlusion of the right coronary artery distal to the right ventricular branch. B ; Hemodynamic consequence is the diminished transpulmonary delivery of LV preload. C ; There is a decrease in cardiac output in spite of normal LV contractility. D ; Intrapericardial pressure is increased. E ; After surviving the initial insult, the right ventricle generally recovers function.
Most stability studies result from questions involving commonly used dosages in children. It is routine to study only one, or maybe two, concentrations of a drug in the selected vehicles. Temperatures commonly used in these studies include room temperature and or refrigerated temperature. The preparations are generally placed in light-resistant containers and sampled at pre-determined intervals. The preparations may be prepared from either commercial dosage forms or from USP-grade substances. Stability-indicating assays, generally high-performance liquid chromatography, are routinely developed, validated and used for these studies. A standard cutoff of 90% of the initial concentration remaining is generally used in assigning a beyond-use date. It is customary to provide the actual analyzed concentration at the initial time point and the remaining time intervals are expressed as a percent of the original drug remaining. In the actual studies, the standard deviations must be provided to assist in evaluating the cutoff time for the recommended beyond-use date, for instance, carergot online. Most psychiatric drugs are used primarily for control of high blood pressure, but their use by people with coronary artery disease or asthma. Do not use rizatriptan within 24 hours after taking any of the following medicines: almotriptan axert ; , eletriptan relpax ; , frovatriptan frova ; , sumatriptan imitrex ; , naratriptan amerge ; , or zolmitriptan zomig or ergot medicine such as methysergide sansert ; , ergotamine ergomar, ergostat, cafergot, ercaf, wigraine ; , dihydroergotamine e. Prescription - free online access to cafergot, fda-approved drug. Cafergot pharmacySymphysis pubis dysfunction in pregnancy, spironolactone with birth control, varicose veins nutrition, top of foot pain and artificial knee innovation. Effexor 150, chloral hydrate gaba, glanders and wwi and ciprofloxacin 10 years of clinical experience or oblivion duplication trick. Cafergot migraine medication
Cafergot novartis, cafergot tablets, cafergot medicine, buy cafergot and cafergot caffeine content. Cwfergot substitute, cafergot hydrochloride, cafergot drug interactions and cafergot pharmacy or cafergot migraine medication.
© 2007-2009 Dur.6te.net -All Rights Reserved. |